Atypical Hemolytic Uremic Syndrome: A Brief Review
暂无分享,去创建一个
[1] N. Dunbar,et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue , 2019, Journal of clinical apheresis.
[2] B. Quiroga,et al. A Case Report and Literature Review of Eculizumab Withdrawal in Atypical Hemolytic-Uremic Syndrome , 2016, The American journal of case reports.
[3] G. Deschênes,et al. Long-term successful liver–kidney transplantation in a child with atypical hemolytic uremic syndrome caused by homozygous factor H deficiency , 2016, Pediatric Nephrology.
[4] M. Tran,et al. Atypical Hemolytic Uremic Syndrome Secondary to Lupus Nephritis, Responsive to Eculizumab , 2016, Hematology reports.
[5] J. Montoya,et al. Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis , 2016, Current opinion in infectious diseases.
[6] M. Daha,et al. Can eculizumab be discontinued in aHUS? , 2016, Medicine.
[7] Susan A. Lippold,et al. Notes from the Field: Meningococcal Disease in an International Traveler on Eculizumab Therapy - United States, 2015. , 2016, MMWR. Morbidity and mortality weekly report.
[8] A. Risitano,et al. Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future. , 2016, Seminars in immunology.
[9] N. Dunbar,et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice–Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue , 2016, Journal of clinical apheresis.
[10] T. Miyata,et al. Disease Recurrence After Early Discontinuation of Eculizumab in a Patient With Atypical Hemolytic Uremic Syndrome With Complement C3 I1157T Mutation , 2016, Journal of pediatric hematology/oncology.
[11] L. Weber,et al. Discontinuation of Eculizumab in a Patient With Atypical Hemolytic Uremic Syndrome Due to a Mutation in CFH. , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[12] Ang Li,et al. Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies: the experience of the Harvard TMA Research Collaborative , 2015, British journal of haematology.
[13] K. Miśkiewicz,et al. A review of guidance on immunization in persons with defective or deficient splenic function , 2015, British journal of haematology.
[14] E. Conway. HUS and the case for complement. , 2015, Blood.
[15] V. Gouilleux-Gruart,et al. Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule , 2015, mAbs.
[16] R. Torra,et al. Actualización en síndrome hemolítico urémico atípico: diagnóstico y tratamiento: Documento de consenso , 2015 .
[17] G. Remuzzi,et al. Glomerular Diseases Dependent on Complement Activation, Including Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis, and C3 Glomerulopathy: Core Curriculum 2015 , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[18] G. Ardissino,et al. Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[19] C. Bedrosian,et al. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. , 2015, Blood.
[20] J. Davin,et al. Advances and challenges in the management of complement-mediated thrombotic microangiopathies , 2015, Therapeutic advances in hematology.
[21] J. Wetzels,et al. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[22] J. Raval,et al. How we approach an acquired thrombotic thrombocytopenic purpura patient , 2014, Transfusion.
[23] G. Ardissino,et al. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[24] G. Ardissino,et al. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome , 2014, Journal of thrombosis and haemostasis : JTH.
[25] O. Ohara,et al. A Complement Factor B Mutation in a Large Kindred with Atypical Hemolytic Uremic Syndrome , 2014, Journal of Clinical Immunology.
[26] K. Dahan,et al. Eculizumab in Anti-Factor H Antibodies Associated With Atypical Hemolytic Uremic Syndrome , 2014, Pediatrics.
[27] G. Ariceta,et al. An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome , 2014, Pediatric Nephrology.
[28] J. Hofer,et al. Complement Factor H-Antibody–Associated Hemolytic Uremic Syndrome: Pathogenesis, Clinical Presentation, and Treatment , 2014, Seminars in Thrombosis & Hemostasis.
[29] A. Sinha,et al. Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. , 2014, Kidney international.
[30] D. Geary,et al. Successful treatment of DEAP-HUS with eculizumab , 2014, Pediatric Nephrology.
[31] S. Cataland,et al. Diagnosis and management of complement mediated thrombotic microangiopathies. , 2014, Blood reviews.
[32] O. Lambotte,et al. Hemolysis and schistocytosis in the emergency department: consider pseudothrombotic microangiopathy related to vitamin B12 deficiency. , 2013, QJM : monthly journal of the Association of Physicians.
[33] G. Remuzzi,et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. , 2013, The New England journal of medicine.
[34] L. Rostaing,et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. , 2013, Clinical journal of the American Society of Nephrology : CJASN.
[35] John Hwa,et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome , 2013, Nature Genetics.
[36] G. Rijkers,et al. Meningococcal Sepsis Complicating Eculizumab Treatment Despite Prior Vaccination , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[37] G. Remuzzi,et al. Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. , 2013, Journal of the American Society of Nephrology : JASN.
[38] J. George,et al. Evaluation of Patients with Microangiopathic Hemolytic Anemia and Thrombocytopenia , 2013, Seminars in Thrombosis & Hemostasis.
[39] J. George,et al. Diagnostic and therapeutic challenges in the thrombotic thrombocytopenic purpura and hemolytic uremic syndromes. , 2012, Hematology. American Society of Hematology. Education Program.
[40] G. Ardissino,et al. Eculizumab for Atypical Hemolytic Uremic Syndrome Recurrence in Renal Transplantation , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[41] S. Vesely,et al. Thrombotic microangiopathic syndromes associated with drugs, HIV infection, hematopoietic stem cell transplantation and cancer. , 2012, Presse medicale.
[42] S. Talluri,et al. Pseudo-thrombotic thrombocytopenic purpura: A rare presentation of pernicious anemia , 2011, North American journal of medical sciences.
[43] J. George. Systemic malignancies as a cause of unexpected microangiopathic hemolytic anemia and thrombocytopenia. , 2011, Oncology.
[44] M. Caligiuri,et al. A sheep in wolf's clothing. , 2011, Blood.
[45] G. Remuzzi,et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. , 2010, Clinical journal of the American Society of Nephrology : CJASN.
[46] E. Rondeau,et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. , 2010, Journal of the American Society of Nephrology : JASN.
[47] Eric Rondeau,et al. Predictive Features of Severe Acquired ADAMTS13 Deficiency in Idiopathic Thrombotic Microangiopathies: The French TMA Reference Center Experience , 2010, PloS one.
[48] P. Barlow,et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. , 2010, Blood.
[49] Giuseppe Remuzzi,et al. Atypical hemolytic-uremic syndrome. , 2009, The New England journal of medicine.
[50] M. López-Trascasa,et al. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. , 2009, Blood.
[51] C. Sautès-Fridman,et al. The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome , 2009, Journal of Medical Genetics.
[52] J. Davin,et al. Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation , 2008, Pediatric Nephrology.
[53] P. Zipfel,et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. , 2008, Blood.
[54] B. Boudailliez,et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. , 2007, Journal of the American Society of Nephrology : JASN.
[55] G. Remuzzi,et al. Screening for complement system abnormalities in patients with atypical hemolytic uremic syndrome. , 2007, Clinical journal of the American Society of Nephrology : CJASN.
[56] J. Goodship,et al. Deletion of Complement Factor H–Related Genes CFHR1 and CFHR3 Is Associated with Atypical Hemolytic Uremic Syndrome , 2007, PLoS genetics.
[57] S. Vesely,et al. Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: A report of 10 patients and a systematic review of published cases. , 2006, The oncologist.
[58] G. Remuzzi,et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. , 2006, Blood.
[59] A. Cnaan,et al. Non-enteropathic hemolytic uremic syndrome: causes and short-term course. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[60] B. Guidet,et al. Schizocytosis in pernicious anemia mimicking thrombotic thrombocytopenic purpura. , 2003, The American journal of medicine.
[61] S. D. Subba Rao,et al. Atypical hemolytic uremic syndrome. , 2002, Indian pediatrics.
[62] S. Cutillo. [Hemolytic-uremic syndrome]. , 1973, La Pediatria.
[63] G. Remuzzi,et al. A novel atypical hemolytic uremic syndrome-associated hybrid CFHR1/CFH gene encoding a fusion protein that antagonizes factor H-dependent complement regulation. , 2015, Journal of the American Society of Nephrology : JASN.
[64] R. Coppo,et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children , 2015, Pediatric Nephrology.
[65] S. Rodríguez de Córdoba,et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. , 2015, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.